Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer

Cancer Investigation

Volumn 23, Issue 5, 2005, Pages 392-398

  Grunberg, Steven M ^a,c   Dugan, Matthew C ^a   Greenblatt, Marc S ^a   Ospina, David J ^b   Valentine, John W ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b Mountainview Medical Group   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Chemotherapy; Lung cancer; Non platin; Synergistic

Indexed keywords

ANTINEOPLASTIC AGENT; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME; VINBLASTINE;

EID: 24944500394     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-67137     Document Type: Article

References (27)

1. Kosmidis, P.; Mylonakis, N.; Nicolaides, C.; Kalophonos, C.; Samantas, E.; et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 2002, 20 (17), 3578-3585.
2. Rosell, R.; Gatzemeier, U.; Betticher, D.C.; Keppler, U.; Macha, H.N.; et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. 2002, 13 (10). 1539-1549.
3. Manegold, C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 2001, 34 (Suppl. 2), S165-S170.
4. Stupp. R.; Bodmer, A.; Duvoisin, B.; Bauer, J.; Percy, L.; el al. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 2001, 61 (Suppl. 1), 35-41.
5. Zhou, X.J.; Rahrnani, R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992, 44 (Suppl. 4), 1-16.
6. Binet, S.; Chaineau, E.; Fellous, A.; Lataste, H.; Krikorian, A.; Couzinier, J.P.; Meininger, V. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int. J. Cancer 1990, 46 (2), 262-266.
7. Abal, M.; Andreu, J.M.; Barasoain, I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 2003, 3 (3), 193-203.
8. Depierre, A.; Lemarie, E.; Dabouis, G.; Gamier, G.; Jacoulet, P.; Dalphin, J.C. Efficacy of navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin. Oncol. 1989, 16 (2 Suppl. 4), 26-29.
9. Rowinsky, E.K.; Onetto, N.; Canetta, R.M.; Arbuck, S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 1992, 19 (6), 646-662.
10. Knick, V.C.; Eberwein, D.J.; Miller, C.G. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl. Cancer Inst. 1995, 87 (14), 1072-1077.
11. Miller, A.B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. Cancer 1981, 47 (1), 207-214.
12. Ginopoulos, P.; Kontomanolis, E.; Kardamakis, D.; Sougleri, M.; Rathosis, S.; et al. A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer. Lung Cancer 2002, 38 (2), 199-203.
13. Perez, J.E.; Machiavelli, M.R.; Romero, A.O.; Romero Acuna, L.A.; et al. Vinorelbine and paclitaxel for locoregional advanced or metastatic non-small-cell lung cancer. Am. J. Clin. Oncol. 2002, 25 (4), 383-387.
14. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346 (2), 92-98.
15. Retsas, S.; Mohith, A.; Mackenzie, H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anti-cancer Drugs 1996, 7 (2), 161-165.
16. Budman, D.R.; Calabro, A.; Wang, L.G.; Liu, X.M.; Stiel, L.; Adams, L.M.; Kreis, W. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Investig. 2000, 18 (8), 695-701.
17. Culine, S.; Roch, I.; Pinguet, F.; Romieu, G.; Bressolle, F. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int. J. Oncol. 1999, 14 (5), 999-1006.
18. Kano, Y.; Akutsu, M.; Suzuki, K.; Ando, J.; Tsunoda, S. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res. Treat. 1999, 56 (1), 79-90.
19. Jung, M.; Grunberg, S.; Timblin, C.; Buder-Hoffman, S.; et al. Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549). Histochem. Cell Biol. 2004, 121 (2), 115-121.
20. Cohen, R.B.; Mueller, S.C.; Haden, K.; de Souza, P. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Investig. 2000, 18 (5), 422-428.
21. Perry, M.C.; Ihde, D.C.; Herndon, J.E.; Grossbard, M.L.; Grethein, S.J.; Atkins, J.N. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000, 28 (1), 63-68.
22. Budman, D.R.; Weiselberg, L.; O'Mara, V.; Buchbinder, A.; Lichtman, S.M.; Donahue, L. A phase I study of sequential vinorelbine followed by paclitaxel. Ann. Oncol. 1999, 10 (7), 861-863.
23. Aoe, K.; Kiura, K.; Ueoka, H.; Tabata, M.; Matsumura, T.; Chikamori, M. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. 1999, 19 (1A), 291-299.
24. Bennouna, J.; Monnier, A.; Riviere, A.; Milleron, B.; Lemarie, E.; Trillet-Lenoir, V. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur. J. Cancer 2000, 36 (9), 1107-1112.
25. Miller, V.A.; Krug, L.M.; Ng, K.K.; Pizzo, B.; Oerez, W.; Heelan, R.T. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2000, 18 (6), 1346-1350.
26. Wang, L.G.; Liu, X.M.; Kreis. W.; Budman, D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999, 44 (5), 355-361.
27. Krug, L.M.; Miller, V.A.; Filippa, D.A.; Venkatraman, E.; Ng, K.K.; Kris, M.G. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 2003, 39 (2), 139-143.